Blog: MALLINCKRODT PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01. Regulation FD Disclosure.

On September 14, 2022, Mallinckrodt plc issued a press release announcing that
the U.S. Food and Drug Administration approved Terlivaz® (terlipressin) for
injection. A copy of the press release is being furnished as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01, including Exhibit 99.1, shall be
deemed to be “furnished” and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall such
information be deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d)      Exhibits.

Exhibit No.   Description of Exhibit
   99.1         Press Release, dated September 14, 2022.
    104       Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s